{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzlseq\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzlseq\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/53\\\/19\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/53\\\/19\u0022}],\u0022ac\u0022:{\u0022spmdc;14\\\/53\\\/19\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;14\\\/53\\\/19\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003ELung cancer is the number one cause of cancer deaths in both men and women in the United States and around the world. To provide an overview of current and future imaging options, 5 specialists highlighted new concepts in the staging, imaging, and management of lung cancer.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Erespiratory cancers\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Emagnetic resonance imaging\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Etomography\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\n         \n         \u003Cp id=\u0022p-2\u0022\u003ELung cancer is the number one cause of cancer deaths in both men and women in the United States and around the world [American Cancer Society. \u003Ca href=\u0022http:\/\/www.cancer.org\/cancer\/lungcancer-non-smallcell\/detailedguide\/non-small-cell-lung-cancer-key-statistics\u0022\u003Ehttp:\/\/www.cancer.org\/cancer\/lungcancer-non-smallcell\/detailedguide\/non-small-cell-lung-cancer-key-statistics\u003C\/a\u003E. Accessed January 12, 2015]. To provide an overview of current and future imaging options, 5 specialists highlighted new concepts in the staging, imaging, and management of lung cancer.\u003C\/p\u003E\n         \u003Cp id=\u0022p-3\u0022\u003EFergus V. Gleeson, MBBS, Churchill Hospital, Headington, Oxford, United Kingdom, discussed contemporary concepts in small-cell lung cancer (SCLC). SCLC accounts for up to 15% of bronchogenic carcinomas [National Cancer Institute. \u003Ca href=\u0022http:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/small-cell-lung\/healthprofessional\/page1#_6_toc\u0022\u003Ehttp:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/small-cell-lung\/healthprofessional\/page1#_6_toc\u003C\/a\u003E. Accessed January 12, 2015] and around 20% of all lung cancers [Riaz SP et al. \u003Cem\u003ELung Cancer.\u003C\/em\u003E 2012]; most cases are attributable to smoking [Kalemkerian GP et al. \u003Cem\u003EJ Natl Compr Canc Netw.\u003C\/em\u003E 2013]. SCLC is characterized by its rapid growth, high response rates to both chemotherapy and radiotherapy, and development of treatment resistance in patients with metastatic disease [Fr\u00fch M. \u003Cem\u003EAnn Oncol.\u003C\/em\u003E 2013]. Incidence rates, however, appear to be falling [National Cancer Institute. \u003Ca href=\u0022http:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/small-cell-lung\/healthprofessional\/page1#_6_toc\u0022\u003Ehttp:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/small-cell-lung\/healthprofessional\/page1#_6_toc\u003C\/a\u003E. Accessed January 12, 2015].\u003C\/p\u003E\n         \u003Cp id=\u0022p-4\u0022\u003EPatients commonly present with anorexia, cough, hemoptysis, pain, as well as abnormal chest radiograph or computed tomography (CT) images; about 90% have a hilar mass and bulky lymphadenopathy [Carter BW et al. \u003Cem\u003ERadiographics.\u003C\/em\u003E 2014]. It is unusual to find a solitary pulmonary nodule, and metastases are most commonly identified in the bone, liver, adrenal glands, and brain. Imaging for SCLC includes contrast-enhanced CT of the chest and liver, contrast-enhanced brain magnetic resonance imaging (MRI), and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (18-F-FDG) positron emission tomography (PET)-CT.\u003C\/p\u003E\n         \u003Cp id=\u0022p-5\u0022\u003EManagement of localized disease (T1 to T4; N0 to 3; M0) is shown in \u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E. Approximately 5% of patients with SCLC present with T1,2 N0,1 M0 tumors. These patients have more favorable survival outcomes over 5 years compared with patients with more severe disease [Schreiber D et al. \u003Cem\u003ECancer.\u003C\/em\u003E 2010; Yu JB et al. \u003Cem\u003EJ Thorac Oncol.\u003C\/em\u003E 2010].\u003C\/p\u003E\n         \u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/14\/53\/19\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022European Society of Medical Oncology Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-Up of Patients With Small-Cell Lung Cancer\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-209540267\u0022 data-figure-caption=\u0022European Society of Medical Oncology Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-Up of Patients With Small-Cell Lung Cancer\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/14\/53\/19\/F1.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/14\/53\/19\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/14\/53\/19\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16490\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption attrib\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \n               \u003Cp id=\u0022p-6\u0022 class=\u0022first-child\u0022\u003EEuropean Society of Medical Oncology Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-Up of Patients With Small-Cell Lung Cancer\u003C\/p\u003E\n            \u003Cq class=\u0022attrib\u0022 id=\u0022attrib-1\u0022\u003E*If no confirmation of solitary metastasis is obtained, radiotherapy may be added after first response evaluation and is omitted in case of obvious metastatic involvement.\u003C\/q\u003E\u003Cq class=\u0022attrib\u0022 id=\u0022attrib-2\u0022\u003E**Concomitant chemoradiotherapy as an alternative option.\u003C\/q\u003E\u003Cq class=\u0022attrib\u0022 id=\u0022attrib-3\u0022\u003E***Or stable disease in case of localised disease.\u003C\/q\u003E\u003Cq class=\u0022attrib\u0022 id=\u0022attrib-4\u0022\u003EReproduced from Fr\u00fch M et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 (suppl 6):vi99\u2013vi105. By permission of European Society for Medical Oncology.\u003C\/q\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n         \u003Cp id=\u0022p-7\u0022\u003EPrognostic factors include the extent of disease, metabolic activity, paraneoplastic syndromes, elevated lactate dehydrogenase and creatinine, no histological or molecular features, and referral directly from a family doctor to a chest physician [Foster NR et al. \u003Cem\u003ECancer.\u003C\/em\u003E 2009]. Treatment options are surgery, radiotherapy, and chemotherapy [Powell HA et al. \u003Cem\u003EBr J Cancer.\u003C\/em\u003E 2014]. The accuracy of staging is critical in the management of SCLC. Brain MRI should be performed at presentation, and surgery should be considered in patients with T1,2 and N0,1 disease.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-2\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003ENSCLC STAGING: CONCEPTS AND CONTROVERSIES\u003C\/h2\u003E\n         \u003Cp id=\u0022p-8\u0022\u003EIoannis Vlahos, MBBS, St George\u0027s Hospital NHS Trust, London, United Kingdom, highlighted the concepts and controversies associated with the staging of non\u2013small cell lung cancer (NSCLC). The defined purpose of a staging system is to categorize disease severity, accurately predict prognosis, and guide patient management. The staging process should be easy to implement; should be logical, unambiguous, and reproducible; and should use all appropriate current imaging methodologies. The impetus for changing the TNM Classification of Malignant Tumors (TNM) staging system included evidence regarding technical improvement, such as the use of CT imaging and resection for NSCLC with intrapulmonary metastases.\u003C\/p\u003E\n         \u003Cp id=\u0022p-9\u0022\u003EThe goals of the most recent (2007) TNM-7 staging system by the International Association for the Study of Lung Cancer were to reclassify TNM descriptors and staging groups according to survival [Goldstraw P et al. \u003Cem\u003EJ Thorac Oncol.\u003C\/em\u003E 2006]. The advantages of TNM-7 compared with TNM-6 include a large patient cohort (varied sources and treatments), clinical\/CT-based staging, and a more accurate stratification of survival (\u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\n         \u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022\/\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/16491\/expansion?postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 html=\u00221\u0022 fragment=\u0022#\u0022 external=\u00221\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/16491\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16491\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \n               \u003Cp id=\u0022p-10\u0022 class=\u0022first-child\u0022\u003EComparison of Data Sources Between Editions of the IASLC TNM\u003C\/p\u003E\n            \u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n         \u003Cp id=\u0022p-13\u0022\u003ETNM-8, with expected publication in 2016, will address retrospective limitations, use a shorter data collection period (2009 to 2012), and make a series of changes for T, N, and M. It will also include histology, PET standard uptake values, comorbidities, and pulmonary function tests.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-3\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EPET IMAGING IN NSCLC\u003C\/h2\u003E\n         \u003Cp id=\u0022p-14\u0022\u003EEric M. Rohren, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, Texas, USA, discussed PET imaging of lung cancer. Although surgical resection remains the optimal treatment for early-stage NSCLC, approximately 40% of patients with stage I and 60% of those with stage II NSCLC relapse and die within 5 years of curative resection, indicating a need for additional prognostic biomarkers [Hyun SH et al. \u003Cem\u003EAnn Surg.\u003C\/em\u003E 2013]. Dr Rohren reviewed published data that evaluated the prognostic significance and predictive performance of volume-based parameters of 18-F-FDG PET-CT in early-stage NSCLC. According to Hyun and colleagues [\u003Cem\u003EAnn Surg.\u003C\/em\u003E 2013], the volume-based parameter of PET is an independent prognostic factor for survival and pathological TNM stage, and is a promising tool for better prediction of outcome in patients with early-stage NSCLC.\u003C\/p\u003E\n         \u003Cp id=\u0022p-15\u0022\u003EDr Rohren also discussed non\u221218-F-FDG positron emission radiotracers for molecular imaging in oncology. These are used to measure glucose metabolism, cellular catabolism, receptors, membrane synthesis, proliferation, hypoxia, and bone turnover. New tracers under development and nearing regulatory approval in the United States include tracers targeting proliferation, receptor expression, and protein catabolism, as well as investigating molecular events and processes beyond glucose metabolism.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-4\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EADVANCES IN NODULE CHARACTERIZATION AND LUNG CANCER STAGING WITH MRI\u003C\/h2\u003E\n         \u003Cp id=\u0022p-16\u0022\u003EKyung Soo Lee, MD, Samsung Medical Center, Seoul, Korea, presented information about available MRI sequences for thoracic imaging; diffusion-weighted imaging (DWI) and its application in left coronary artery (LCA) imaging; and whole-body MRI and fusion imaging of MRI-PET in LCA staging.\u003C\/p\u003E\n         \u003Cp id=\u0022p-17\u0022\u003ERefined sequences in thoracic MRI include T2-weighted fast spin-echo for infiltrates and parenchymal lesions; T2-weighted fast spin-echo with fat saturated for lymph nodes (LNs) and bone lesions; T1W FS 3D-gradientecho for nodules and masses; steady-state free procession images for respiratory motion and lung vasculature; and DWI and fat saturated for nodule and LN characterization.\u003C\/p\u003E\n         \u003Cp id=\u0022p-18\u0022\u003EDWI can be used to perform single-shot echo-planar imaging and to measure microscopic water mobility (Brownian motion). Besides providing functional information, it can also be used to enhance image diffusion and process due to increased cellularity, fibrosis, and changes in intercellular spaces [Kwee TC et al. \u003Cem\u003EEur Radiol.\u003C\/em\u003E 2008; Nomori H et al. \u003Cem\u003EJ Thorac Cardiovasc Surg.\u003C\/em\u003E 2008; Ohno Y et al. \u003Cem\u003ERadiology.\u003C\/em\u003E 2008].\u003C\/p\u003E\n         \u003Cp id=\u0022p-19\u0022\u003EMany advantages are associated with whole-body DWI with background body signal suppression. Multiple signal averaging, background body signal suppression by FS prepulse, and heavy DW in free-breathing state enable clinicians to highlight areas of restricted diffusion in primary malignancies and metastatic tumors, and visualize metastatic LNs [Kwee TC et al. \u003Cem\u003EEur Radiol.\u003C\/em\u003E 2008]. These images can be useful in cancer staging, response evaluation, and restaging.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-5\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003ECT PERFUSION IMAGING IN LUNG CANCER\u003C\/h2\u003E\n         \u003Cp\u003EFriedrich D. Knollmann, MD, University of California Davis Medical Center, Sacramento, California, USA, discussed the potential roles of computed tomography perfusion (CTP) imaging in tumor imaging, including the following:\n\u003C\/p\u003E\u003Cul class=\u0022list-unord \u0022 id=\u0022list-1\u0022\u003E\u003Cli id=\u0022list-item-1\u0022\u003E\n                  \u003Cp id=\u0022p-21\u0022\u003EDetermination of tumor type, stage, and spread\u003C\/p\u003E\n               \u003C\/li\u003E\u003Cli id=\u0022list-item-2\u0022\u003E\n                  \u003Cp id=\u0022p-22\u0022\u003ETumor detection\u003C\/p\u003E\n               \u003C\/li\u003E\u003Cli id=\u0022list-item-3\u0022\u003E\n                  \u003Cp id=\u0022p-23\u0022\u003ETreatment planning\u003C\/p\u003E\n               \u003C\/li\u003E\u003Cli id=\u0022list-item-4\u0022\u003E\n                  \u003Cp id=\u0022p-24\u0022\u003EDetermination of treatment response\u003C\/p\u003E\n               \u003C\/li\u003E\u003Cli id=\u0022list-item-5\u0022\u003E\n                  \u003Cp id=\u0022p-25\u0022\u003ERestaging\u003C\/p\u003E\n               \u003C\/li\u003E\u003Cli id=\u0022list-item-6\u0022\u003E\n                  \u003Cp id=\u0022p-26\u0022\u003EDetection of tumor recurrence or metastatic disease\u003C\/p\u003E\n               \u003C\/li\u003E\u003C\/ul\u003E\u003Cp\u003E\n         \u003C\/p\u003E\n         \u003Cp id=\u0022p-27\u0022\u003EAlthough CTP is an attractive biomarker in lung cancer, there are challenges in using it to assess treatment response in lung cancer. These include anatomic coverage, respiratory motion, temporal resolution, determining an appropriate radiation dose, a dual blood supply of lung cancer, and the lack of standardized technique and analysis. Dr Knollmann gave an example of the difficulties in achieving anatomic coverage. This requires the following: a detector size of 2\/4\/16 cm; table motion that allows for axial and helical shuttle; table motion that reduces the sampling rate (sampling rates \u0026gt; 1 seconds influence perfusion parameters [Ng CS et al. \u003Cem\u003EAJR Am J Roentgenol.\u003C\/em\u003E 2013]); a sampling interval that does not exceed 2 seconds [Miles KA et al. \u003Cem\u003EEur Radiol.\u003C\/em\u003E 2012]; and coverage of at least 4 cm.\u003C\/p\u003E\n         \u003Cp id=\u0022p-28\u0022\u003EHe then discussed potential solutions to these problems, such as improved anatomic coverage with wider detectors and table motion, reduced radiation exposure with iterative reconstruction, advanced postprocessing with dual blood supply algorithms, motion registration and correction, and volumetric perfusion analysis.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-6\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003ETHORACIC ONCOLOGIC IMAGING: TREATMENT EFFECTS AND COMPLICATIONS\u003C\/h2\u003E\n         \u003Cp id=\u0022p-29\u0022\u003EBrett W. Carter, MD, University of Texas, Houston, Texas, USA, spoke about the role of imaging in patients who have been treated with radiation therapy, chemotherapy, or surgery for intrathoracic malignancies.\u003C\/p\u003E\n         \u003Cp id=\u0022p-30\u0022\u003EAmong the surgical procedures for lung cancer\u2014pneumonectomy, lobectomy, and sublobar resection\u2014there are differences in the complication rate and risk of recurrence. Radiation therapy is typically one component of multimodality therapy for lung cancer, esophageal cancer, and lymphoma. Treatment plans are variable and depend on several factors.\u003C\/p\u003E\n         \u003Cp id=\u0022p-31\u0022\u003EThe imaging appearance of irradiated tissue varies according to the time that has elapsed since the radiation. This can range from the ground-glass opacity of radiation pneumonitis (1 to 6 months) to the volume loss, consolidation, and traction bronchiectasis seen at 6 to 12 months. Patients who have undergone radiation are at risk of pulmonary embolism, esophagitis, ulceration, metastatic disease, hepatic injury, and radiation-induced sarcoma. Complications from chemotherapy include drug-induced pulmonary toxicity, pulmonary embolism, and arterial and venous thrombosis.\u003C\/p\u003E\n         \u003Cp id=\u0022p-32\u0022\u003EDr Carter emphasized that CT and PET\/CT are the modalities of choice in evaluating patients who have undergone surgery, radiation therapy, or chemotherapy. Knowledge of the spectrum of expected treatment-related changes, potential treatment complications, and how to identify tumor recurrence is critical in order to properly monitor patients, identify iatrogenic complications, and avoid misinterpretation.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2015 MD Conference Express\u00ae\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/14\/53\/19.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_figures.js?nzlseq\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzlseq\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_tables.js?nzlseq\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}